Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population
Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population
复制标题
DOI：
10.4269/ajtmh.2005.73.244
复制
发表时间：
2005-08-01
影响因子：
3.3
通讯作者：
Galinski, MR
中科院分区：
文献类型：
--
作者：
Tran, TM;Oliveira-Ferreira, J;Galinski, MR
对来自巴西朗多尼亚州三个疟疾流行社区的294名献血者进行了对两种主要间日疟原虫候选疫苗的自然获得性抗体反应性调查。比较了间日疟原虫网织红细胞结合蛋白1 （PvRBP1）和达菲结合蛋白（PvDBP-RII） 5个不同区重组表达抗原的抗体识别情况。根据年龄校正后，对这些抗原的IgG阳性反应与过去感染和在流行地区居住年限的疟疾暴露水平显著相关。抗PvRBP1总IgG抗体的最高患病率对应于氨基酸区域PvRBP1(431-748)（41%）和PvRBP1(733-1407)（47%）。大约五分之一的阳性反应血清的滴度至少为1:16 00。与单个PvRBP1抗原相比，PvDBP-RII的总IgG应答更为普遍（67%），更大程度，获得速度更快。对PvRBP1和PvDBP-RII的反应偏向于嗜细胞亚类IgG1和IgG3。这些数据首次提供了对PvRBP1获得性抗体反应的见解，并与PvDBP-RII进行了比较，这可能对理解对这两种候选疫苗的保护性免疫反应有价值，因为它们被评估为多靶点血期疫苗的组成部分。
Naturally acquired antibody reactivity to two major Plasmodium vivax vaccine candidates was investigated in 294 donors from three malaria-endemic communities of Rondonia state, Brazil. Antibody recognition of recombinantly expressed antigens covering five different regions of P. vivax reticulocyte binding protein 1 (PvRBP1) and region II of P. vivax Duffy binding protein (PvDBP-RII) were compared. Positive IgG responses to these antigens were significantly related to the level of malaria exposure in terms of past infections and years of residence in the endemic area when corrected for age. The highest prevalence of anti-PvRBP1 total IgG antibodies corresponded to the amino acid regions denoted PvRBP1(431-748) (41 %) and PvRBP1(733-1407) (47%). Approximately one-fifth of positively responding sera had titers of at least 1:1,600. Total IgG responses to PvDBP-RII were more prevalent (67%), of greater magnitude, and acquired more rapidly than those to individual PvRBP1 antigens. Responses to both PvRBP1 and PvDBP-RII were biased toward the cytophilic subclasses IgG1 and IgG3. These data provide the first insights on acquired antibody responses to PvRBP1 and a comparative view with PvDBP-RII that may prove valuable for understanding protective immune responses to these two vaccine candidates as they are evaluated as components of multitarget blood-stage vaccines.